PortfoliosLab logoPortfoliosLab logo
BOUT vs. IMCG
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BOUT vs. IMCG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Innovator IBD Breakout Opportunities ETF (BOUT) and iShares Morningstar Mid-Cap Growth ETF (IMCG). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BOUT achieves a 31.39% return, which is significantly higher than IMCG's 20.05% return.


BOUT

1D
-0.01%
1M
5.85%
YTD
31.39%
6M
30.30%
1Y
35.27%
3Y*
17.42%
5Y*
8.25%
10Y*

IMCG

1D
-0.26%
1M
8.33%
YTD
20.05%
6M
18.28%
1Y
23.35%
3Y*
18.91%
5Y*
8.62%
10Y*
14.46%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BOUT vs. IMCG - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BOUT
Innovator IBD Breakout Opportunities ETF
31.39%-6.77%18.82%13.27%-22.60%22.69%50.56%20.59%-29.80%
IMCG
iShares Morningstar Mid-Cap Growth ETF
20.05%6.55%18.14%20.73%-25.79%15.39%45.64%35.70%-17.84%

Correlation

The correlation between BOUT and IMCG is 0.79, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.79

Correlation (3Y)
Calculated over the trailing 3-year period

0.83

Correlation (5Y)
Calculated over the trailing 5-year period

0.78

Correlation (All Time)
Calculated using the full available price history since Sep 14, 2018

0.80

The correlation between BOUT and IMCG has been stable across timeframes, ranging from 0.78 to 0.83 - a consistent structural relationship.

BOUT vs. IMCG - Sectors Allocation Comparison


Sectors
BOUT
IMCG

Technology

28.4%
30.4%

Financial Services

22.9%
9.1%

Basic Materials

9.9%
4.5%

Consumer Defensive

9.7%
1.2%

Industrials

9.7%
26.6%

Consumer Cyclical

8.5%
10.0%

Utilities

7.0%
2.7%

Real Estate

3.5%
3.4%

Energy

3.1%
2.1%

Healthcare

2.6%
7.4%

Communication Services

2.0%
2.6%

Technology

BOUT
28.4%
IMCG
30.4%

Financial Services

BOUT
22.9%
IMCG
9.1%

Basic Materials

BOUT
9.9%
IMCG
4.5%

Consumer Defensive

BOUT
9.7%
IMCG
1.2%

Industrials

BOUT
9.7%
IMCG
26.6%

Consumer Cyclical

BOUT
8.5%
IMCG
10.0%

Utilities

BOUT
7.0%
IMCG
2.7%

Real Estate

BOUT
3.5%
IMCG
3.4%

Energy

BOUT
3.1%
IMCG
2.1%

Healthcare

BOUT
2.6%
IMCG
7.4%

Communication Services

BOUT
2.0%
IMCG
2.6%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BOUT vs. IMCG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BOUT
BOUT Risk / Return Rank: 5151
Overall Rank
BOUT Sharpe Ratio Rank: 4949
Sharpe Ratio Rank
BOUT Sortino Ratio Rank: 4747
Sortino Ratio Rank
BOUT Omega Ratio Rank: 4646
Omega Ratio Rank
BOUT Calmar Ratio Rank: 6161
Calmar Ratio Rank
BOUT Martin Ratio Rank: 5353
Martin Ratio Rank

IMCG
IMCG Risk / Return Rank: 4444
Overall Rank
IMCG Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
IMCG Sortino Ratio Rank: 4242
Sortino Ratio Rank
IMCG Omega Ratio Rank: 4040
Omega Ratio Rank
IMCG Calmar Ratio Rank: 4646
Calmar Ratio Rank
IMCG Martin Ratio Rank: 5252
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BOUT vs. IMCG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Innovator IBD Breakout Opportunities ETF (BOUT) and iShares Morningstar Mid-Cap Growth ETF (IMCG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BOUTIMCGDifference
Sharpe ratioReturn per unit of total volatility

+0.19

Sortino ratioReturn per unit of downside risk

+0.15

Omega ratioGain probability vs. loss probability

1.30

1.26

+0.03

Calmar ratioReturn relative to maximum drawdown

3.01

2.31

+0.70

Martin ratioReturn relative to average drawdown

9.00

8.97

+0.03

BOUT vs. IMCG - Sharpe Ratio Comparison

The current BOUT Sharpe Ratio is 1.71, which is comparable to the IMCG Sharpe Ratio of 1.51. The chart below compares the historical Sharpe Ratios of BOUT and IMCG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BOUTIMCGDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.71

1.51

+0.19

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.43

0.43

0.00

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.71

Sharpe Ratio (All Time)

Calculated using the full available price history

0.41

0.54

-0.13

Drawdowns

BOUT vs. IMCG - Drawdown Comparison

The maximum BOUT drawdown since its inception was -36.75%, smaller than the maximum IMCG drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for BOUT and IMCG.


Loading charts...

Drawdown Indicators


BOUTIMCGDifference

Max Drawdown

Largest peak-to-trough decline

-36.75%

-58.96%

+22.21%

Max Drawdown (1Y)

Largest decline over 1 year

-11.76%

-10.17%

-1.59%

Max Drawdown (3Y)

Largest decline over 3 years

-25.31%

-21.92%

-3.39%

Max Drawdown (5Y)

Largest decline over 5 years

-28.28%

-35.08%

+6.80%

Max Drawdown (10Y)

Largest decline over 10 years

-35.08%

Current Drawdown

Current decline from peak

-0.01%

-0.26%

+0.25%

Average Drawdown

Average peak-to-trough decline

-12.29%

-9.22%

-3.07%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.93%

2.61%

+1.32%

Volatility

BOUT vs. IMCG - Volatility Comparison

Innovator IBD Breakout Opportunities ETF (BOUT) has a higher volatility of 5.96% compared to iShares Morningstar Mid-Cap Growth ETF (IMCG) at 4.65%. This indicates that BOUT's price experiences larger fluctuations and is considered to be riskier than IMCG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BOUTIMCGDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.96%

4.65%

+1.31%

Volatility (6M)

Calculated over the trailing 6-month period

16.05%

12.53%

+3.52%

Volatility (1Y)

Calculated over the trailing 1-year period

20.79%

15.53%

+5.26%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

19.48%

20.17%

-0.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.93%

20.51%

+2.42%

BOUT vs. IMCG - Expense Ratio Comparison

BOUT has a 0.80% expense ratio, which is higher than IMCG's 0.06% expense ratio.


Dividends

BOUT vs. IMCG - Dividend Comparison

BOUT's dividend yield for the trailing twelve months is around 0.26%, less than IMCG's 0.65% yield.


PositionTTM20252024202320222021202020192018201720162015
BOUT
Innovator IBD Breakout Opportunities ETF
0.26%0.34%0.60%1.32%1.35%0.00%0.00%0.00%0.22%0.00%0.00%0.00%
IMCG
iShares Morningstar Mid-Cap Growth ETF
0.65%0.78%0.78%0.85%0.91%0.41%0.09%0.30%0.35%0.45%0.52%0.38%

Frequently Asked Questions


BOUT and IMCG have a correlation of 0.79, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BOUT has higher volatility (5.96%) compared to IMCG (4.65%). In terms of maximum drawdown, BOUT dropped -36.75% vs IMCG's -58.96%.

On 5-year performance, IMCG leads with 8.62% vs 8.25% for BOUT. On fees, IMCG is cheaper at 0.06% per year. On volatility, IMCG has been the lower-risk option at 4.65%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, IMCG has performed better with a 8.62% return vs 8.25%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IMCG is cheaper with a 0.06% expense ratio, compared with 0.80% for BOUT.

IMCG has the higher dividend yield at 0.65%, compared with 0.26% for BOUT.

BOUT tracks IBD Breakout Stocks Total Return Index, while IMCG tracks Morningstar US Mid Cap Broad Growth Index. They also come from different issuers: Innovator and iShares. Their fees differ too: 0.80% for BOUT and 0.06% for IMCG.

BOUT currently has the higher Sharpe Ratio (1.71 vs 1.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BOUT and IMCG

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer